Ensign Peak Advisors, Inc Revance Therapeutics, Inc. Transaction History

Ensign Peak Advisors, Inc

  • $56.1 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
BUY
$4.65 - $9.31 $78,966 - $158,102
16,982 Added 33.73%
67,332 $331,000
Q4 2023

Feb 14, 2024
BUY
$5.81 - $11.2 $77,563 - $149,520
13,350 Added 36.08%
50,350 $442,000
Q4 2022

Feb 13, 2023
BUY
$18.32 - $30.66 $278,464 - $466,032
15,200 Added 69.72%
37,000 $683,000
Q1 2022

May 16, 2022
BUY
$12.36 - $20.31 $105,925 - $174,056
8,570 Added 64.78%
21,800 $425,000
Q4 2021

Feb 11, 2022
BUY
$12.46 - $27.87 $164,845 - $368,720
13,230 New
13,230 $216,000

Others Institutions Holding RVNC

# of Institutions
234
Shares Held
82.8M
Call Options Held
680K
Put Options Held
896K
View Full List

About Revance Therapeutics, Inc.

RVNC Quotes by TradingView
  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email